HK Stock MarketDetailed Quotes

MABPHARM-B (02181)

Watchlist
  • 0.460
  • -0.025-5.15%
Noon Break Apr 9 11:15 CST
1.90BMarket Cap30.67P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

MABPHARM-B (02181) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
Drug sales income598.15M92.58%
独家推广许可权收入43.62M6.75%
Material sales income3.19M0.49%
合同研发生产协议收入943K0.15%
提供合约服务收入191K0.03%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
Drug sales income598.15M92.58%
独家推广许可权收入43.62M6.75%
Material sales income3.19M0.49%
合同研发生产协议收入943K0.15%
提供合约服务收入191K0.03%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
The mainland of China646.1M100.00%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +0.56%
Sample Name
Sample Code
 -3.56%
Sample Name
Sample Code
 -6.21%
4
CHINA OILFIELD
02883
-6.77%
5
KUNLUN ENERGY
00135
-10.44%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +21.31%
Sample Name
Sample Code
 +13.61%
Sample Name
Sample Code
 +8.13%
4
Hangzhou Shunwang Technology
300113
-4.73%
5
Rockchip Electronics
603893
-9.01%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -